Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

News
Tech

Reuters Reported Earlier: Tesla Readies Revamp Of Model Y Codenamed ‘Juniper’

https://www.reuters.com/business/autos-transportation/tesla-readies-revamp-model-y-codenamed-juniper-sources-2023-03-01/

byCharles Gross

March 1, 2023

1 minute read

https://www.reuters.com/business/autos-transportation/tesla-readies-revamp-model-y-codenamed-juniper-sources-2023-03-01/

FDA
News

Sorrento Begins Enrollment In Phase 2 Trial Of Resiniferatoxin For The Treatment Of Pain Due To Knee Osteoarthritis

By Benzinga Newsdesk

Today, 12:30 PM

Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", , Sorrento", , )))) today announced that the Phase 2 clinical study of RTX for treating knee pain from osteoarthritis (OA) has begun enrollment. This study is a

SRNE

Keybanc Maintains Overweight on EOG Resources, Raises Price Target to $97

By Benzinga Newsdesk

Today, 12:30 PM

Keybanc analyst Leo Mariani maintains EOG Resources (NYSE:EOG) with a Overweight and raises the price target from $94 to $97.

EOG

Credit Suisse Maintains Neutral on Huntington Ingalls Indus, Lowers Price Target to $244

By Benzinga Newsdesk

Today, 12:30 PM

Credit Suisse analyst Scott Deuschle maintains Huntington Ingalls Indus (NYSE:HII) with a Neutral and lowers the price target from $259 to $244.

HII

Amylyx Pharmaceuticals Announces Health Canada Approval Of ALBRIOZA For The Treatment Of ALS

By Benzinga Newsdesk

Today, 12:30 PM

Health Canada decision signifies the first global regulatory approval for Amylyx and the first new therapy for ALS approved in Canada since 2018 ALBRIOZA (also known as AMX0035) is an oral fixed-dose

AMLX

Reuters Reported Earlier: Tesla Readies Revamp Of Model Y Codenamed ‘Juniper’

Related Posts

Sorrento Begins Enrollment In Phase 2 Trial Of Resiniferatoxin For The Treatment Of Pain Due To Knee Osteoarthritis

Keybanc Maintains Overweight on EOG Resources, Raises Price Target to $97

Credit Suisse Maintains Neutral on Huntington Ingalls Indus, Lowers Price Target to $244

Amylyx Pharmaceuticals Announces Health Canada Approval Of ALBRIOZA For The Treatment Of ALS